Andrew A. Bogan, PhD Managing Member
Andrew is a Founder and Managing Member of Bogan Associates, LLC. Prior to managing global equity funds, his background was in scientific research and early-stage venture capital investing. Andrew manages investments in a variety of science, technology, and infrastructure industries in 20 countries. In 2014, he was recognised by Wealth & Finance International magazine’s Wealth & Money Management Awards, being named Best Head Fund Manager - Massachusetts.
He has spoken at international investor conferences on the topic of global equity investing in a dozen cities spread over four continents. Andrew has also been interviewed on live television for CNBC's Strategy Session and Street Signs. He has previously lived in the European Union, Korea, and Japan.
Prior to starting Bogan Associates, Andrew was a Venture Partner at Tallwood Venture Capital in Palo Alto, California where he developed and implemented Tallwood's bioscience investment strategy from late 2000 to 2003. At Tallwood, Andrew sourced investment opportunities, led bioscience due diligence, and made investment recommendations to the partnership. He was an observer on the board of directors for several portfolio companies in the bioscience and semiconductor industries, including Infinity Pharmaceuticals (NASDAQ: INFI), Inphi (NYSE: IPHI), Signature BioScience, and T-RAM Semiconductor. Andrew has also made several independent venture capital investments including Amyris (NASDAQ: AMRS), Catalyst Biosciences, and Sunesis Pharmaceuticals (NASDAQ: SNSS). As a venture capitalist, he was invited to speak at the MIT Sloan Venture Capital and Principal Investment Association and judged business plans for the UCSF BioEntrepreneurship Symposium and for the Princeton University Business Plan Contest.
Before joining Tallwood, Andrew spent the summer of 2000 as a Visiting Scientist at Sankyo Pharmaceuticals in Tokyo, Japan on a National Science Foundation fellowship. At Sankyo (now Daiichi-Sankyo), he worked in the Exploratory Chemistry Research Laboratory on a series of thiazolidinedione molecules in development to treat type 2 diabetes. Andrew spent over 6 years doing scientific research at Princeton University, Genentech, UCSF, and Sankyo which led to the publication of half a dozen papers in peer-reviewed scientific journals. He has given scientific research seminars at Affymax, Tularik (now Amgen), Sankyo, UCSF, and the Korea Institute of Science and Technology.
Andrew holds an A.B. in Molecular Biology and a Certificate in Materials Science and Engineering from Princeton University. He earned his Ph.D. in Biophysics from the University of California, San Francisco, where he was a United States Department of Defense Graduate Fellow and recipient of UCSF’s Kozloff Fellowship, awarded for excellence in graduate research. He has passed the Series 65 Exam.